ReviewJournal of clinical and experimental hepatology
Magnitude of Nonalcoholic Fatty Liver Disease: Eastern Perspective.
Review in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Characterization of gut microbiome signatures in metabolic dysfunction associated steatotic liver disease.NPJ biofilms and microbiomes · 2026Article
- Article
- Neutrophils in MASLD and MASH.BMB reports · 2025Review
- SLC11A1 protein as a key regulator of iron metabolism, ferroptosis mediator, and putative therapeutic target in nonalcoholic fatty liver disease: an integrated bioinformatics analysis.Frontiers in pharmacology · 2025Article
- Sex differences in diet-induced MASLD - are female mice naturally protected?Frontiers in endocrinology · 2025Article
- Development and validation of a predictive nomogram for the risk of MAFLD in postmenopausal women.Frontiers in endocrinology · 2024Article
- NAFLD vs MAFLD: South Asian NAFLD Patients don't Favor Name Change.Euroasian journal of hepato-gastroenterology · 2022Article
- A Lard and Soybean Oil Mixture Alleviates Low-Fat-High-Carbohydrate Diet-Induced Nonalcoholic Fatty Liver Disease in Mice.Nutrients · 2022Article
- Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights.Clinical and molecular hepatology · 2020Article
- Genetic Susceptibility to Chronic Liver Disease in Individuals from Pakistan.International journal of molecular sciences · 2020Article
- Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders.Nature reviews. Gastroenterology & hepatology · 2020Review
- Demographic Profile and Etiology of Hepatocellular Carcinoma in Zaria, Northern Nigeria.Nigerian medical journal : journal of the Nigeria Medical AssociationArticle
- Nonalcoholic Fatty Liver Disease: Lessons Learnt in the Last Five Years.Journal of clinical and experimental hepatologyArticle
- Living Donor Liver Transplant in Patients Aged 60 Years or Older: Experience from a Large Volume Centre in India.Journal of clinical and experimental hepatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease worldwide, affecting a quarter of the global adult population. Nonalcoholic steatohepatitis, the more active form of NAFLD with active hepatic necroinflammation and faster fibrosis progression, has become one of the leading indications for liver transplantation and an important cause of hepatocellular carcinoma in Western countries. Epidemiological studies suggest that NAFLD is almost equally prevalent in Asia as in the West, but severe liver complications appear to be less common. In this article, we review the epidemiology, clinical characteristics, risk factors and clinical outcomes of NAFLD in Asia. We highlight the issue of NAFLD in the nonobese population and discuss whether it is a unique phenomenon in Asia. Because of the rapidly changing epidemiology and natural history, future studies should continue to monitor the magnitude of NAFLD in Asia and define the best policy to control this new epidemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.